Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M.

J Infect Dis. 2017 Feb 1;215(3):335-343. doi: 10.1093/infdis/jiw542.

2.

Dominant drug targets suppress the emergence of antiviral resistance.

Tanner EJ, Liu HM, Oberste MS, Pallansch M, Collett MS, Kirkegaard K.

Elife. 2014 Nov 3;3. doi: 10.7554/eLife.03830.

3.

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. Review.

PMID:
25316866
4.

First use of investigational antiviral drug pocapavir (v-073) for treating neonatal enteroviral sepsis.

Torres-Torres S, Myers AL, Klatte JM, Rhoden EE, Oberste MS, Collett MS, McCulloh RJ.

Pediatr Infect Dis J. 2015 Jan;34(1):52-4. doi: 10.1097/INF.0000000000000497.

PMID:
25229269
5.

Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Liu HM, Roberts JA, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS, Oberste MS.

Antimicrob Agents Chemother. 2012 Nov;56(11):5568-74. doi: 10.1128/AAC.00539-12. Epub 2012 Aug 13.

6.

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM.

Antivir Ther. 2011;16(7):999-1004. doi: 10.3851/IMP1838.

PMID:
22024515
7.

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM.

Clin Vaccine Immunol. 2011 Aug;18(8):1387-90. doi: 10.1128/CVI.05147-11. Epub 2011 Jun 29.

8.

Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus.

Rumyantsev AA, Zhang ZX, Gao QS, Moretti N, Brown N, Kleanthous H, Delagrave S, Guirakhoo F, Collett MS, Pugachev KV.

Virology. 2010 Jan 20;396(2):329-38. doi: 10.1016/j.virol.2009.10.033. Epub 2009 Nov 12.

9.

In vitro antiviral activity of V-073 against polioviruses.

Oberste MS, Moore D, Anderson B, Pallansch MA, Pevear DC, Collett MS.

Antimicrob Agents Chemother. 2009 Oct;53(10):4501-3. doi: 10.1128/AAC.00671-09. Epub 2009 Jul 27.

10.

The discovery of pyrano[3,4-b]indole-based allosteric inhibitors of HCV NS5B polymerase with in vivo activity.

Laporte MG, Jackson RW, Draper TL, Gaboury JA, Galie K, Herbertz T, Hussey AR, Rippin SR, Benetatos CA, Chunduru SK, Christensen JS, Coburn GA, Rizzo CJ, Rhodes G, O'Connell J, Howe AY, Mansour TS, Collett MS, Pevear DC, Young DC, Gao T, Tyrrell DL, Kneteman NM, Burns CJ, Condon SM.

ChemMedChem. 2008 Oct;3(10):1508-15. doi: 10.1002/cmdc.200800168. No abstract available.

PMID:
18729128
11.

A case for developing antiviral drugs against polio.

Collett MS, Neyts J, Modlin JF.

Antiviral Res. 2008 Sep;79(3):179-87. doi: 10.1016/j.antiviral.2008.04.002. Epub 2008 May 13. Review.

PMID:
18513807
12.

N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors.

Bailey TR, Rippin SR, Opsitnick E, Burns CJ, Pevear DC, Collett MS, Rhodes G, Tohan S, Huggins JW, Baker RO, Kern ER, Keith KA, Dai D, Yang G, Hruby D, Jordan R.

J Med Chem. 2007 Apr 5;50(7):1442-4. Epub 2007 Mar 3.

13.

Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS.

Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9.

14.

Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.

Ledford RM, Collett MS, Pevear DC.

Antiviral Res. 2005 Dec;68(3):135-8. Epub 2005 Sep 19.

PMID:
16199099
15.

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R.

J Virol. 2005 Oct;79(20):13139-49.

16.

Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s).

Yang G, Pevear DC, Collett MS, Chunduru S, Young DC, Benetatos C, Jordan R.

J Virol. 2004 Sep;78(18):10202-5.

17.

VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.

Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC.

J Virol. 2004 Apr;78(7):3663-74.

18.

The newly characterized colicin Y provides evidence of positive selection in pore-former colicin diversification.

Riley MA, Cadavid L, Collett MS, Neely MN, Adams MD, Phillips CM, Neel JV, Friedman D.

Microbiology. 2000 Jul;146 ( Pt 7):1671-7.

PMID:
10878131
19.

Mechanism of action of a pestivirus antiviral compound.

Baginski SG, Pevear DC, Seipel M, Sun SC, Benetatos CA, Chunduru SK, Rice CM, Collett MS.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7981-6.

23.

Pestivirus NS3 (p80) protein possesses RNA helicase activity.

Warrener P, Collett MS.

J Virol. 1995 Mar;69(3):1720-6.

24.

Pestivirus translation initiation occurs by internal ribosome entry.

Poole TL, Wang C, Popp RA, Potgieter LN, Siddiqui A, Collett MS.

Virology. 1995 Jan 10;206(1):750-4.

25.

Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes.

Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS.

J Virol. 1993 Oct;67(10):6152-8.

26.

Generation of neutralizing anti-B19 parvovirus human monoclonal antibodies from patients infected with human immunodeficiency virus.

Arakelov S, Gorny MK, Williams C, Riggin CH, Brady F, Collett MS, Zolla-Pazner S.

J Infect Dis. 1993 Sep;168(3):580-5.

PMID:
8354899
27.

Candidate recombinant vaccine for human B19 parvovirus.

Bansal GP, Hatfield JA, Dunn FE, Kramer AA, Brady F, Riggin CH, Collett MS, Yoshimoto K, Kajigaya S, Young NS.

J Infect Dis. 1993 May;167(5):1034-44.

PMID:
8486937
28.
29.
30.

Rearrangement of viral sequences in cytopathogenic pestiviruses.

Meyers G, Tautz N, Stark R, Brownlie J, Dubovi EJ, Collett MS, Thiel HJ.

Virology. 1992 Nov;191(1):368-86.

PMID:
1329326
31.

Dipeptide backbone conformation and antibody recognition of a viral octapeptide epitope.

Feller DC, Collett MS.

Biopolymers. 1992 Oct;32(10):1407-15.

PMID:
1384748
32.

Molecular genetics of pestiviruses.

Collett MS.

Comp Immunol Microbiol Infect Dis. 1992 Jul;15(3):145-54. Review.

PMID:
1325329
33.

Baculovirus expression of pestivirus non-structural proteins.

Petric M, Yolken RH, Dubovi EJ, Wiskerchen M, Collett MS.

J Gen Virol. 1992 Jul;73 ( Pt 7):1867-71.

PMID:
1321220
34.

Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Rosenfeld SJ, Yoshimoto K, Kajigaya S, Anderson S, Young NS, Field A, Warrener P, Bansal G, Collett MS.

J Clin Invest. 1992 Jun;89(6):2023-9. Erratum in: J Clin Invest 1992 Dec;90(6):2609.

35.
36.

Efficiency of various cloned DNA probes for detection of bovine viral diarrhea viruses.

Kwang J, Littledike ET, Bolin S, Collett MS.

Vet Microbiol. 1991 Aug 15;28(3):279-88.

PMID:
1654669
38.

Bovine viral diarrhea virus genomic organization.

Collett MS, Wiskerchen M, Welniak E, Belzer SK.

Arch Virol Suppl. 1991;3:19-27.

PMID:
9210922
39.

Bunyaviridae genome structure and gene expression.

Elliott RM, Schmaljohn CS, Collett MS.

Curr Top Microbiol Immunol. 1991;169:91-141. Review. No abstract available.

PMID:
1935231
40.
41.

Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation.

Kakach LT, Suzich JA, Collett MS.

Virology. 1989 Jun;170(2):505-10.

PMID:
2728348
42.

Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, Collett MS, Suzich JA, Schmaljohn AL.

Virology. 1989 May;170(1):184-92.

PMID:
2655274
43.

Recent advances in pestivirus research.

Collett MS, Moennig V, Horzinek MC.

J Gen Virol. 1989 Feb;70 ( Pt 2):253-66. Review. No abstract available.

PMID:
2471785
44.

The development of biosynthetic vaccines.

Collett MS.

Adv Vet Sci Comp Med. 1989;33:109-72. Review. No abstract available.

PMID:
2648773
45.

CD15 monoclonal antibodies react with a phosphotyrosine-containing protein on the surface of human neutrophils.

Skubitz KM, Mendiola JR, Collett MS.

J Immunol. 1988 Dec 15;141(12):4318-23.

PMID:
2461989
46.

Comparisons of the pestivirus bovine viral diarrhoea virus with members of the flaviviridae.

Collett MS, Anderson DK, Retzel E.

J Gen Virol. 1988 Oct;69 ( Pt 10):2637-43.

PMID:
2844971
47.

Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins.

Wasmoen TL, Kakach LT, Collett MS.

Virology. 1988 Sep;166(1):275-80.

PMID:
3046119
48.

Proteins encoded by bovine viral diarrhea virus: the genomic organization of a pestivirus.

Collett MS, Larson R, Belzer SK, Retzel E.

Virology. 1988 Jul;165(1):200-8.

PMID:
2838958
49.
50.

Supplemental Content

Loading ...
Support Center